ArticleNPJ digital medicine2025
Diagnostic digital phenotyping in schizophrenia-spectrum disorders: a systematic review.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Polysomnographic Parameters in Schizoaffective Disorder: A Systematic Review and Meta-Analysis.Alpha psychiatry · 2026Pooled it
- Schizophrenia: Converging Neurobiological Mechanisms and Emerging Therapeutic Strategies.Biomolecules · 2026Review
- A review of the application of digital phenotyping in predicting peripartum depressive symptoms.NPJ digital medicine · 2026Article
- From neuroinflammation to neural inference: computational psychiatry meets precision medicine.Schizophrenia (Heidelberg, Germany) · 2026Review
- AI-enabled passive digital phenotyping of experiential negative symptoms in schizophrenia-spectrum disorders: a narrative review on the path from sensing to clinical endpoints.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital phenotyping offers a promising but heterogeneous approach for assessing schizophrenia-spectrum disorders (SSD). This systematic review, the first of its kind, comprehensively analyzes the diagnostic and predictive utility of digital phenotyping in SSD. Following PRISMA guidelines, we synthesized data from 142 peer-reviewed studies (2004-2024; n = 6294 participants). Results show a predominance of smartphone and wearable-based approaches, with only ~20% of studies combining active and passive methods. Among six symptom domains, cognitive performance yielded the largest pooled effect size (Hedges' g ≈ 1.20) for differentiating individuals with SSD from controls, followed by behavior and activity (g ≈ 0.62). However, both domains exhibited very high heterogeneity (I² > 70%). Correlations with the PANSS scale were scarce (<5% of studies), with coefficients reaching 0.6. Relapse prediction models showed promise, with some AUC values reaching 0.8, but lacked methodological standardization. This review highlights the potential of specific digital measures while underscoring the urgent need for improved reporting, multimodal data integration, and longitudinal studies with diverse populations to enhance diagnostic and predictive power in SSD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.